Real-Time Ketone Monitoring Could Make a Common Type 1 Diabetes Drug Safer

SGLT2 inhibitors are a class of medication that helps people with Type 1 diabetes by improving kidney function and reducing glucose in the bloodstream. However, they carry a particular risk: they can increase ketone production, sometimes leading to euglycemic diabetic ketoacidosis (euDKA)—a life-threatening condition where ketones build up to dangerous levels.

What makes euDKA especially tricky is that it can happen even when blood sugar remains normal or only mildly elevated. Standard warning signs like very high blood glucose may not appear, making the condition harder to recognize and treat quickly.

Continuous ketone monitoring is a new technology that tracks beta-hydroxybutyrate—the main ketone the body produces—in real time. Unlike older methods such as urine ketone strips or finger-prick tests, CKM provides ongoing measurements and trend data.

By detecting rising ketone levels as they happen, rather than waiting for them to accumulate, CKM could identify problems earlier—potentially before a person feels sick or before ketones reach dangerous levels.

If continuous ketone monitoring proves reliable, it could open the door to wider, safer use of SGLT2 inhibitors in Type 1 diabetes. Real-time ketone data would help doctors and patients understand when to adjust medications or insulin, when to eat specific foods, or when to seek medical care.

Researchers are also exploring dual sensors that track both glucose and ketones at the same time. These could eventually work with automated insulin delivery systems—the kind of technology that adjusts insulin automatically based on blood sugar trends—to manage both glucose and ketone levels together.

Although continuous ketone monitoring is promising, it remains an emerging technology. Before it becomes standard care, several important questions need answers: What ketone levels should trigger an alert? How do we know when someone needs to take action? Does using CKM actually prevent euglycemic diabetic ketoacidosis and other serious outcomes?

Research is underway to validate this technology and define the thresholds that matter clinically. Once those questions are answered, continuous ketone monitoring could become a valuable safety tool for people using SGLT2 inhibitors or other therapies that raise ketone risk.

Source: Endocrinology and metabolism clinics of North America. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.